- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Liraglutide reduces bone marrow adipogenesis by miR-150-5p/ GDF11 axis in diabetic rats. (Pubmed Central) - Jul 26, 2024
In vivo, liraglutide reversed the HFD-STZ induced excessive lipid droplets by up-regulation of GDF11 expression, which was discounted by agomiR-150-5p injection. Above all, liraglutide might alleviate bone marrow fat accumulation via inactivating miR-150-5p/GDF11 axis in diabetes.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Liraglutide alleviated Alpha-pyrrolidinovalerophenone (?-PVP) induced Cognitive deficits in rats by modifying brain mitochondrial impairment. (Pubmed Central) - Jul 26, 2024
Our results showed Liraglutide ameliorated ?-PVP induced spatial learning and memory impairments through alleviating brain mitochondrial dysfunctions (which is indicated by increasing ROS formation, collapsed MMP, mitochondrial outer membrane damage, cytochrome c release, mitochondrial swelling, and brain ADP/ATP ratio) in rats. This study could be used as a starting point for future studies about the possible role of Liraglutide in mitochondrial dysfunction related to cognitive impairments due to substance use disorder.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Liraglutide impacts iron homeostasis in a murine model of hereditary hemochromatosis. (Pubmed Central) - Jul 24, 2024
Importantly, our data shows that liraglutide alters iron metabolism in HFE KO mice, leading to decreased circulating and stored iron levels in HFE KO mice. These observations highlight the potential that GLP1RA could be utilized to reduce iron overload in addition to reducing body weight and improving glucose regulation in HH patients.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Trial termination: Efficacy of Liraglutide Therapy in Patients With IPAA (clinicaltrials.gov) - Jul 23, 2024
P2, N=8, Terminated,
Despite certain deficiencies, GLP-1 RAs have considerable potential for the treatment of eating disorders. Completed --> Terminated; Due to an interruption in drug supply, the study was terminated
- |||||||||| Clinical, Review, Journal: Medications for Obesity: A Review. (Pubmed Central) - Jul 22, 2024
Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Trial completion, Enrollment change, Trial completion date: The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans (clinicaltrials.gov) - Jul 22, 2024
P4, N=97, Completed,
Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes. Unknown status --> Completed | N=35 --> 97 | Trial completion date: May 2021 --> Nov 2023
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Trial termination: EMPOWER-T2D: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial (clinicaltrials.gov) - Jul 22, 2024
P4, N=74, Terminated,
The study was closed due to futility. All Patients are off study and this study will not resume.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Observational data, Retrospective data, Journal: Retinopathy risk factors in patients with type 2 diabetes on liraglutide. (Pubmed Central) - Jul 19, 2024
In conclusion, liraglutide use caused significant reductions in the HbA1c level and weight of patients with T2D. Most patients showed no change in retinopathy status after liraglutide use.
- |||||||||| GLUCAGON-LIKE PEPTIDE RECEPTOR 1 ANALOGUE COULD REDUCE ALCOHOL INTAKE IN PEOPLE WITH ALCOHOL USE DISORDER: A SYSTEMATIC REVIEW (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_274;
A prospective cohort control study showed people on semaglutide or tirzepatide (n=153) compared to no medication significantly reduced number of alcoholic drinks consumed and binge drinking (p<0.05)...Functional brain imaging suggested significant reductions in cue reactivity were observed in the ventral striatum [F(1,31) = 4.744, P = 0.037, partial ?2 = 0.133], dorsal striatum [F(1,31) = 6.124, P = 0.019, partial ?2 = 0.165], and putamen [F(1,31) = 4.730, P = 0.037, partial ?2 = 0.132] after 26 weeks of exenatide treatment compared with placebo (Table 1). GLP-1 RAs show promise in reducing alcohol consumption and improving outcomes in individuals with AUD, although heterogeneous study findings warrant further research to establish true effectiveness and safety of GLP-1 RAs in AUD.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
GLP-1 Receptor Agonists Attenuate Pain-Like Behavior in an Animal Model of Chronic Migraine (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1945;
Unlike propranolol, GLP-1 receptor agonists beneficially affect spontaneous pain-like behavior and animal well-being. Assuming the high predictive value of the employed chronic pain model, semaglutide and liraglutide might represent useful alternatives for chronic migraine prophylaxis.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Clinical, Journal, Real-world evidence, Real-world: Liraglutide in the management of obesity: real world data (Portugal). (Pubmed Central) - Jul 16, 2024
Mean weight loss was significant and more evident from the 6th month of treatment on. Liraglutide, along with lifestyle intervention, is a good option for weight management in the majority of patients with obesity.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Phase classification, Trial termination: Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity. (clinicaltrials.gov) - Jul 16, 2024
P1, N=13, Terminated,
Liraglutide, along with lifestyle intervention, is a good option for weight management in the majority of patients with obesity. Phase classification: P2 --> P1 | Completed --> Terminated; The study was initially paused due to COVID restrictions and then when able to resume, there was no longer funding.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Subthreshold activation of the melanocortin system causes generalized sensitization to anorectic agents in mice. (Pubmed Central) - Jul 15, 2024
We observed enhanced neuronal activation in multiple hypothalamic nuclei using Fos IHC following low-dose liraglutide in MC3R-KO mice (Mc3r-/-), supporting the hypothesis that the MC3R is a negative regulator of circuits that control multiple aspects of feeding behavior. The enhanced anorectic response in Mc3r-/- mice after administration of GLP1 analogs was also independent of the incretin effects and malaise induced by GLP1 receptor (GLP1R) analogs, suggesting that MC3R antagonists or MC4R agonists may have value in enhancing the dose-response range of obesity therapeutics.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice. (Pubmed Central) - Jul 13, 2024
The enhanced anorectic response in Mc3r-/- mice after administration of GLP1 analogs was also independent of the incretin effects and malaise induced by GLP1 receptor (GLP1R) analogs, suggesting that MC3R antagonists or MC4R agonists may have value in enhancing the dose-response range of obesity therapeutics. Our findings suggest that liraglutide could promote brown remodeling of visceral WAT by bi-regulating miRNAs; this might be one of the mechanisms underlying its effect on weight loss.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Observational data, Journal, HEOR, Real-world evidence, Treatment costs, Real-world: The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy. (Pubmed Central) - Jul 4, 2024
Limitations included exclusion of patients using insulin at GLP-1 RA initiation and collection of HCRU data by physician, not via patient-completed diaries. Real-world HCRU and costs associated with the treatment of adults with T2D with two GLP-1 RAs in TROPHIES emphasize the need to avoid generalization with respect to HCRU and costs associated with a particular therapy when estimating the impact of a new treatment in a country-specific setting.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1. (Pubmed Central) - Jul 1, 2024
Real-world HCRU and costs associated with the treatment of adults with T2D with two GLP-1 RAs in TROPHIES emphasize the need to avoid generalization with respect to HCRU and costs associated with a particular therapy when estimating the impact of a new treatment in a country-specific setting. This study suggests that FDX1 could serve as a potential biomarker for elucidating the underlying mechanisms of liraglutide's therapeutic effects in PCOS management.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient. (Pubmed Central) - Jun 30, 2024
The Adverse Drug Reaction Probability Scale suggested a high likelihood of a causative association between liraglutide and his symptoms. Our report highlights the importance of vigilance in monitoring for these potential adverse effects among adolescents treated for obesity with any dose of liraglutide.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Journal: Time to unshackle the medical treatment of obesity in the NHS. (Pubmed Central) - Jun 27, 2024
Liraglutide can improve glycolipid metabolism and microinflammatory status in patients with abdominal obesity and type 2 diabetes, which has high medication safety. The glucagon-like peptide-1 (GLP-1) receptor analogues, such as once-daily subcutaneous Liraglutide 3.0 mg (Saxenda
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Sex-Differences in Response to Treatment with Liraglutide 3.0 mg. (Pubmed Central) - Jun 27, 2024
This study showed a greater therapeutic effect of liraglutide 3.0 mg in men. Given men's higher risk of cardiovascular disease (CVD), and underrepresentation in clinical weight loss programs, these findings may increase male engagement and improve their CVD risk.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Anesthesia and GLP-1 Agonists: A retrospective chart review (Exhibit Hall) - Jun 25, 2024 - Abstract #ASA2024ASA_597;
To power the Chi-squared tests, a significance level of ?=0.01, power of 0.95 and a small effect size of 0.05, the calculated sample size was n=26486In conclusion, we found that pneumonitis, aspiration, and ARDS were not significantly associated with GLP-1 agonists, when controlling for age, sex, race, BMI, and comorbidities categorized by the Elixhauser Comorbidity Index (Tables 3-5). There was no significant association between types of GLP-1 agonists (liraglutide vs semaglutide) and pneumonitis, when controlling for age, sex, race, BMI, and comorbidities (Table 6).
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database. (Pubmed Central) - Jun 24, 2024
Analysis of the US Food and Drug Administration's adverse events reporting system database has shown that certain GLP1RAs, particularly exenatide, semaglutide and liraglutide, were associated with a higher proportion of respiratory adverse events, particularly asthma or asthma-like events...However, the reasons for these differences in the adverse event profiles of the GLP1RAs remain unclear and may involve various factors such as pharmacological properties, patient characteristics and reporting biases. The complex interplay between the therapeutic benefits of GLP1RAs and the potential respiratory risks requires careful monitoring by clinicians, underpinned by ongoing research efforts to improve patient care and safety.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Preclinical, Journal: Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist. (Pubmed Central) - Jun 23, 2024
Our study suggests that oral GENE/PTCA formulation could be a promising alternative to injection-based therapeutics for diabetics, which is effective in long-term treatment and has been found to be highly safe in all aspects of toxicology. The strong reductions of body weight in response to long-term applications of the triple agonist GEP44 confirms the therapeutic potential of targeting multiple receptors for achieving more robust and potentially more sustained improvement of energy balance.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Journal: Glucagon-like peptide-1 analog liraglutide reduces fat deposition in chicken adipocytes. (Pubmed Central) - Jun 22, 2024
Collectively, our findings indicate that liraglutide suppresses the proliferation of preadipocytes, enhances their differentiation, and concurrently inhibits de novo lipogenesis in mature adipocytes. This observation offers profound insights into the mechanisms that underlie liraglutide's anti-adipogenic effects, which could have significant implications for the treatment of obesity in broiler chickens.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Trial completion date, Trial primary completion date: Liraglutide Effects on Epicardial Fat Inflammatory Genes (clinicaltrials.gov) - Jun 21, 2024
P4, N=40, Recruiting,
This observation offers profound insights into the mechanisms that underlie liraglutide's anti-adipogenic effects, which could have significant implications for the treatment of obesity in broiler chickens. Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Incretin receptor agonists rapidly and markedly attenuate multi-cause insulin resistance in the hippocampal formation from MCI and AD dementia cases (121 ABC (Pennsylvania Convention Center)) - Jun 19, 2024 - Abstract #AAIC2024AAIC_4657;
Using our ex vivo stimulation protocol (Talbot et al., 2012), tissue sections were tested for insulin-induced phosphorylation of insulin signaling and regulating enzymes after 30 min incubations in 0, 1, or 10 nM insulin with or without 30 min preincubation in 100 nM of liraglutide activating GLP-1 (glucagon-like peptide-1) receptors, [D-Ala 2 ]-GIP activating GIP (gastric inhibitory peptide) receptors, or Peptide 19, a dual IRA activating both GLP-1 and GIP receptors... IRAs reaching brain neurons can virtually eliminate hippocampal insulin resistance in naMCI and aMCI cases, but significantly reducing such resistance in ADd cases appears to require a dual IRA.
- |||||||||| Victoza (liraglutide) / Novo Nordisk
Evaluation of Novel GLP-1 analogue in the treatment of Alzheimer's disease (121 ABC (Pennsylvania Convention Center)) - Jun 19, 2024 - Abstract #AAIC2024AAIC_4654;
Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes mellitus (T2DM)... These findings highlight the potential of GLP-1 analogues in the treatment of Alzheimer
|
